Analyst Color

DraftKings Analyst Sees Sports Betting Sector Growth, Positive Outcome From Paul Vs. Tyson Fight
Roaring Kitty Ditched Chewy, Analyst Says You Should Adopt The Stock With 'Path To Pawsitive Growth'
Microsoft 'One Of The Most Compelling Investment Opportunities,' Says Goldman Sachs
Roaring Kitty Ditched Chewy, Analyst Says You Should Adopt The Stock With 'Path To Pawsitive Growth'
Microsoft 'One Of The Most Compelling Investment Opportunities,' Says Goldman Sachs
Stocks Fall Ahead Of Nvidia Earnings, Dollar Resumes Gains, Bitcoin Reaches New Record Highs: What's Driving Markets Wednesday?
WeRide's Robotaxi And Partnerships Are Key Growth Drivers For Global Expansion: Analyst

Analyst Color Recent News

Amazon Remains 'Best Idea' In E-Commerce This Holiday Season, JPMorgan Analyst Says
JPMorgan analyst Doug Anmuth sees strong online sales growth this holiday season and points to Amazon as the firm's "Best Idea" for capturing the momentum.
Carlyle Sells QuidelOrtho Shares, Analyst Sees Overhang Lifted
QuidelOrtho's secondary offering of 8.26 million shares is priced at $38.58, removing an investor overhang, according to William Blair's analysis.
Walmart Posts Q3 Sales Beat, Raises Guidance: Analysts Expect Strong Earnings Growth Ahead
Walmart same-store sales grew by 5.3%, tracking better than consensus of 3.9%. This was driven by traffic being up 3.1%.
Inspire Medical's Strong 2025 Outlook And Upcoming Inspire V Launch Earns Analyst Upgrade
BofA upgrades Inspire Medical to Buy, setting a $255 price target. The company aims for $950 million in 2025 revenue, with a focus on new product launches and expansion.
Target Margins And Inventory Issues Raise Analyst Caution After Weak Q3 Performance
Target's weak Q3 results and lowered FY24 outlook raise concerns over margins, inventory, and digital growth, with analysts expressing caution.
Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside
UCB and Biogen's Phase 3 lupus drug trial shows improved disease activity outcomes, with promising data leading to a second pivotal trial in 2024.
Viking Therapeutics Garners Analyst Support For NASH And Metabolic Programs
Viking Therapeutics' Phase 2b results show VK2809's efficacy in treating NASH, with significant liver fat reductions, NASH resolution, and fibrosis improvement.
Microsoft Defies AI Plateau, Pushes Boundaries With New Scaling Laws
Microsoft's advancements, such as the Copilot "think deeper" feature, suggest a future of AI that continues to scale and deliver.
Billionaire Investor David Einhorn Calls It 'Most Expensive Market Of All Time' As S&P 500 Gains 4% Since Trump's Win: 'Really, Really Pricey'
Einhorn pointed out that while long-term investors might not incur losses, the current high valuations indicate potentially lower returns in the future.
Walmart Market Share Surges As Six-Figure Income Households Drive 75% Of Growth In Q3: 'People Come To Us To Shop As A Primary Destination'
Walmart reported Q3 results, beating estimates and raising guidance. Sales up 5.5%, gross margin up 21 bps, operating income up 8.2%.
As Spirit Airlines Files For Bankruptcy Experts Weigh Potential Impact On Flight Prices: 'This Is Not A Black And White Situation'
Analysts are weighing on Spirit's market share to determine how the airfares will go up in the face of bankruptcy,
Warner Bros. Discovery NBA Deal 'Best Case Scenario': Analyst Says Renewal Structure Could Boost Annual Profit
Warner Bros. Discovery reaching a deal with the NBA that includes some international rights and licensing of "Inside the NBA" could be a win.
Fortinet Targets 45% Growth-Margin Combo, $450 Million Refresh Boost: Analysts See Big Upside
FORTINET, Inc (NASDAQ: FTNT) stock raised by top analysts after strong Q3 earnings report and successful analyst day. Revenue and billings up.

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2024 Benzinga | All Rights Reserved